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Herein, we evaluate the inﬂuence of a PLL–HA bilayer on the surface of silica nanoparticles on their capacity
to induce the osteogenic diﬀerentiation of human bone marrow stem cells (hBMSCs), as a function of their
concentration (50 mg mL1, 25 mg mL1 and 12.5 mg mL1). To this purpose, we synthesized silica
nanoparticles (diameter of 250 nm; z-potential of 25 mV) that were coated with PLL–HA (diameter of
560 nm; z-potential of 35 mV). The cell viability, cell proliferation, protein quantiﬁcation (i.e. MTS,
DNA and ALP, respectively) and gene expression (of osteogenesis-related genes: ALP, osteocalcin,
collagen type I, bone sialoprotein, Runx-2, osteopontin and osterix) were monitored, for 21 days. We
observed the overexpression of most of the tested osteogenic transcripts in the hBMSCs cultured with
SiO2–PLL–HA, at concentrations of 25 mg mL
1 and 12.5 mg mL1. These results indicate that the
proposed nanoparticles temporarily improve the osteogenic diﬀerentiation of hBMSCs at low
nanoparticle concentrations.
1. Introduction
Bioceramics, bioactive glasses and related composite materials,
that combine bioactive inorganic materials with biodegradable
polymers,1 have been extensively studied for biomedical applica-
tions.2,3 Bioactive materials, in particular silica (SiO2) nano-
particles, are considered relevant for bone tissue repair since: (i)
they can be easily biofunctionalized; (ii) they are biocompatible
(presenting osteoconductive and osteoinductive properties); and
(iii) their degradation shows positive biological eﬀects aer
implantation.4,5 In addition, the size of SiO2 nanoparticles can be
tuned tomatch the size range of the integral parts of natural bone,
such as hydroxyapatite crystals or cellular compartments, making
them promising candidates for bone tissue regeneration.6
SiO2 nanoparticles are usually obtained through the sol–gel
methodology; they are produced by low-temperature process-
ing, providing the conditions to synthesize nanoparticles of
diﬀerent compositions. In combination, these characteristics
enable the preparation of monodispersive SiO2 nanoparticles of
diﬀerent controllable sizes.7
Among the diﬀerent techniques used to modify surfaces, the
deposition of polyelectrolyte multilayers (PEMs) has emerged as
a very easy handling and versatile tool. Based on the alternate
adsorption of polycations and polyanions, this technique allows
lms to be built-up with tunable properties. Basically, this
technique consists of the dipping of a material in a poly-
electrolyte solution, which allows the interactions between a
polycation and a polyanion, driving to the construction of a
multilayered system.8 Several studies have reported the
construction of lms onto charged surfaces (e.g. gold, SiO2, etc.)
using this layer-by-layer (LbL) technique exploiting the opposite
charge of poly-L-lysine (PLL) and hyaluronic acid (HA).9,10
The HA is an important component of the natural extracel-
lular matrix (ECM) being present in all tissues. It is a unique,
linear, unmodied glycosaminoglycan consisting of repeating
disaccharide units composed of D-glucuronic acid and D-N-
acetylglucosamine. The HA functions not only as a structural
component, but it can also bind to cells by direct interaction
with cell surface receptors such as CD44. It is able to activate a
series of intracellular signaling pathways, participating in the
regulation of cell migration, proliferation and diﬀerentia-
tion.11,12 Some authors defend that HA induces an increase in
the mesenchymal stem cell (MSC) diﬀerentiation onto the
osteogenic lineage.13On the other hand, PLL, a cationic polymer
at neutral pH, is commonly used as a cell-adhesion agent for
cell-culturing experiments in plates and on other solid
substrates.14 The cationic primary amine groups of the lysine
side chains interact with the negatively charged HA resulting in
a multilayered system, well described in the literature.15–17
PLL–HA can be chemically cross-linked using water-soluble
carbodiimide in combination with N-hydroxysulfosuccinimide.
This cross-linked (PLL–HA)n system has been reported to
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promote the anchoring of primary chondrocytes and smooth
muscle cells, when compared to non cross-linked materials.18
SiO2 nanoparticles are known to be eﬃciently internalized into
human MSCs without aﬀecting cell viability, growth or diﬀer-
entiation.19 MSCs represent a particularly interesting cell type
for research and therapy because of their ability to diﬀerentiate
into mesodermal lineage cells such as osteocytes, chondrocytes,
cardiac muscle, and endothelial cells.20 MSCs can been isolated
from diﬀerent organs and tissues, but the most relevant sources
are the bone marrow and adipose tissue.
The present work describes the processing of bioactive
organic/inorganic nanoparticles, exploiting their chemical and
nano-topological structure, and their ability to induce human
bone marrow MSC (hBMSC) diﬀerentiation towards the osteo-
genic lineage. Previous studies have reported that cells derived
from bone marrow can be stimulated for osteogenesis when in
contact with bioactive glasses.21 Also, PEM systems, based on
PLL–HA are reported to be capable of diﬀerentiating MSCs into
osteocytes and chondrocytes upon culture with induction
factors.22 Taking advantage of the physico-chemical character-
istics of SiO2 nanoparticles and LbL construction, the overall
aim of this work is to synthesize PLL–HA coated SiO2 nano-
particles (Scheme 1) and to investigate their biological activity
over viability, proliferation, and diﬀerentiation of hBMSCs.
2. Experimental
2.1 Materials
Tetraethyl orthosilicate 99% (TEOS), ammonium hydroxide
solution (33%), poly-L-lysine (PLL; Mw 30–70 kDa), N-(3-dime-
thylaminopropyl)-N0-ethylcarbodiimide hydrochloride (EDC) $
98.0% and N-hydroxysuccinimide (NHS) were obtained from
Sigma-Aldrich. Hyaluronic acid (HA; Mw 1.20–1.80 MDa) was
purchased from Lifecore. All the chemicals were used without
further purication. For immunostaining we used phalloidin–
tetramethylrhodamine B isothiocyanate (P1951) and 4,6-dia-
midino-2-phenyindole, dilactate (DAPI) (D9564) from Sigma-
Aldrich. Primary antibodies osteocalcin (ab13418 –mousse anti-
human) and osteopontin (ab14175 – rabbit anti-human) were
purchased from AbCam. Secondary antibodies IgG Alexa Fluor®
488 (A-21202, anti-mouse) and IgG Alexa Fluor® 488 (A21206,
anti-rabbit) were obtained from Invitrogen (Life Technologies).
2.2 Methods
Synthesis of silica nanoparticles. The synthesis of SiO2
nanoparticles was performed as described elsewhere.23 Briey,
monodisperse spherical solid core SiO2 nanoparticles were
synthesized by mixing 8 mL of ammonium hydroxide with a
solution containing 200 mL of absolute ethanol and 16 mL of
deionized water. Aer stirring for 30 min, 24 mL of TEOS was
added to the solution and stirred for 6 h at room temperature.
The as-synthesized SiO2 nanoparticle suspension was centri-
fuged and dried at 70 C overnight. The resulting dry powder
was further calcined at 550 C for 6 h in air in order to remove
organic residues.
Surface coatings. SiO2 nanoparticles were immersed
sequentially into a polycation and polyanion solutions, namely
PLL (0.5 mg mL1) and HA (1 mg mL1), dissolved in 0.15 M
NaCl (pH z 5.5–6.0) to form the polymeric bilayer shell. Each
layer was allowed to form for 15 minutes, followed by a set of
three rinsing steps using a 0.15 M NaCl aqueous solution. Aer
the formation of the bilayer, the polymeric shell was cross-
linked using a mixture of water-soluble EDC (400 mM) and NHS
(100 mM), as described elsewhere.24 The nanoparticles were
stirred overnight at 4 C within the cross-linking solution
(prepared with 0.15 M NaCl, pH z 5.5–6.0). They were nally
rinsed three times with a 0.15 M NaCl solution, generating the
SiO2–bilayer hybrid system (SiO2–PLL–HA).
Surface morphology, size distribution and z-potential
measurements. The surface morphology of the nanoparticles
was examined using a scanning electron microscope (SEM;
Leica S360, Cambridge, UK). The nanoparticles were coated
with gold before the analysis. The size distribution of the
nanoparticles, and their z-potential, were determined by
Dynamic Light Scattering (DLS; Malvern, Zetasizer NANO-ZS).
Chemical analysis of the bilayered system. The surface
chemistry of the nanoparticles was analyzed by Fourier trans-
form infrared spectroscopy (FTIR). The samples were mixed
with potassium bromide (KBr) in a ratio of 1 : 10, sample : KBr
(w/w). The mixture was molded into a transparent pellet using a
press (Pike, USA). Transmission spectra were acquired on an IR
Prestige-21 spectrometer (Shimadzu, Japan), using 32 scans, a
resolution of 4 cm1 and a wavenumber range between 4400
cm1 and 500 cm1.
Expansion, seeding and osteogenic diﬀerentiation of
hBMSCs. hBMSCs were isolated from bone marrow aspirates of
three donors, under established cooperative agreements
between local Hospitals and the 3B's Research Group. The
isolation procedure was performed according to the method
established by Delorme and Charbord25 and the characteriza-
tion of the mesenchymal phenotype has been described in
previous reports.26–28 hBMSCs were expanded in basal medium
consisting of Dulbecco's modied Eagle's medium (DMEM;
Sigma-Aldrich, Germany) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS; Biochrom AG, Germany) and 1%
antibiotic/antimyotic solution (nal concentration of penicillin
100 units mL1 and streptomycin 100 mg mL1; Gibco, UK).
Cells were cultured in a 5% CO2 incubator at 37 C.
Before the in vitro studies, the SiO2–PLL–HA nanoparticles
were sterilized by using ethylene oxide. Conuent hBMSCs, at
passage 4, were harvested, seeded at a density of 1  105 cells
per well of a 24 well-plate and cultured in the presence of the
nanoparticles at concentrations of 50, 25 and 12.5 mg mL1, for
Scheme 1 LbL deposition of PLL and HA onto the surface of the SiO2
nanoparticles.
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7, 14 and 21 days under static conditions, in standard osteo-
genic diﬀerentiation medium (basal medium supplemented
with 50 mg mL1 ascorbic acid, 102 M b-glycerophosphate and
107 M dexamethasone). The assay control condition (SiO2
nanoparticles without bilayer) at 50 mg mL1 and positive
control, were also cultured under standard osteogenic diﬀer-
entiation medium (basal medium supplemented with 50 mg
mL1 ascorbic acid, 10 mM b-glycerophosphate and 107 M
dexamethasone).
Cell morphology and distribution. hBMSC samples were
xed with 2.5% glutaraldehyde (Sigma, Germany) in phosphate
buﬀer saline solution (PBS; Sigma, Germany) and then dehy-
drated through an increasing series of ethanol concentrations
(10%, 20%, 30%, 50%, 70%, 80%, 90% and 100%) and le to
dry overnight. Finally, they were gold sputter-coated (Fisons
Instruments SC502, UK) and observed by SEM (Leica S360,
Cambridge, UK).
Cell viability and proliferation (MTS assay and DNA
content). The hBMSC viability for each culturing time was
determined using the Cell Titer 96® Aqueous One Solution Cell
Proliferation Assay (Promega, USA). This assay is based on the
bioreduction of a tetrazolium compound, 3-(4,5-dimethylth-
iazol-2-yl)-5-(3-carboxymethoxyphe-nyl)-2-(4-sulfofenyl)-2H-tetra-
zolium (MTS), into a water-soluble brown formazan product.
NADPH or NADH production accomplishes this conversion by
the dehydrogenase enzymes in metabolically active cells. The
absorbance was measured at 490 nm using a microplate reader
(Synergie HT, Bio-Tek, USA), being related to the quantity of
formazan product.
Cell proliferation was quantied by the total amount of
double-stranded DNA along the culturing time. Quantication
was performed using the Quant-iT PicoGreen® dsDNA Assay Kit
(Invitrogen, Molecular Probes, Oregon, USA), according to the
manufacturer's instructions. Briey, hBMSCs were lyzed by
osmotic and thermal shock and the supernatant used for the
DNA quantication assay. A uorescent dye, PicoGreen, was
used because of its high sensitivity and specicity to double-
stranded DNA. The uorescence of the dye was measured at an
excitation wavelength of 485/20 nm and at an emission wave-
length of 528/20 nm, in a microplate reader (Synergie HT, Bio-
Tek, USA). Triplicates were carried out for each sample and per
culturing time. The DNA concentration for each sample was
calculated using a standard curve (DNA concentration ranging
from 0.0 to 1.5 mg mL1) relating the quantity of DNA with the
uorescence intensity.
Alkaline phosphatase quantication. The concentration of
alkaline phosphatase (ALP) was determined for all the culture
time periods, using the same samples used for DNA quanti-
cation. Briey, the activity of ALP was assessed using the
p-nitrophenol assay. Nitrophenyl phosphate disodium salt
(pnPP; Fluka BioChemika, Austria), which is colorless, is
hydrolyzed by ALP at pH ¼ 10.5 and a temperature of 37 C to
form free p-nitrophenol, which is yellow. The reaction was
stopped by the addition of 2 M NaOH (Panreac Quimica, Spain)
and the absorbance was read at 405 nm in a microplate reader
(Synergie HT, Bio-Tek, USA). Standards were prepared with 10
mmol mL1 of p-nitrophenol (pNP; Sigma, USA) solution, to
obtain a standard curve ranging from 0.0 to 0.3 mmol mL1.
Quadruplicates of each sample and standard were used, and the
ALP concentrations were calculated from the standard curve.
RNA isolation and real-time quantitative Polymerase Chain
Reaction (qPCR). The total RNA was extracted from the hBMSCs
using the Tri® reagent (Sigma-Aldrich, USA), according to the
manufacturer's instructions. Briey, at each culturing time, the
samples were washed with PBS, immersed in Tri reagent and
stored at 80 C, until further use. Proteins were removed with
chloroform extraction, and the RNA pellets were washed once
with isopropyl alcohol and once with 70% ethanol. Aerwards,
the total RNA pellets were reconstituted in RNAse-free water
(Gibco, Invitrogen, UK). Reverse transcriptase (RT)-PCR was
performed according to the protocol from the iScript cDNA
synthesis kit (Quanta BioSciences™, Gaithersburg, MD, USA).
Briey, a reaction mixture consisting of 1X iScript reaction mix,
1 mL iScript reverse transcriptase, RNA template (up to 1 mg
total RNA) and nuclease-free water was prepared in 20 mL of
total volume. The single-strand cDNA synthesis occurred by
incubating the complete reaction mixture for 5 min at 25 C,
followed by 30 min at 42 C, and was then terminated by an
incubation at 85 C for 5 min. Amplication of the target cDNA
for real-time PCR quantication was performed according to
the manufacturer's instructions, using 2 mL of RT cDNA prod-
ucts, 106 M of each primer 1XiQSYBR Green Supermix (Quanta
BioSciences™, Gaithersburg, MD, USA) and nuclease-free
water, in a nal volume of 20 mL. 44 cycles of denaturation
(95 C, 10 s), annealing (temperature dependent on the gene,
30 s) and extension (72 C, 30 s) were carried out in a Master-
cycler Epgradient SRealplex Thermocycler (Eppendorf,
Hamburg, Germany) for all genes. The transcripts' expression
data were normalized to the housekeeping gene glyceraldehyde-
3-phosphate-dehygrogenase (GAPDH) and the relative quanti-
cation calculated according to the Livak (2DDCT) method using
the standard osteogenic culture condition as the calibrator.
Immunocytochemistry. Osteopontin (OP) and osteocalcin
(OCN) protein expression of hBMSCs was assessed by immu-
nouorescence to evaluate the osteoblastic diﬀerentiation.
hBMSCs grown in tissue culture coverslips were xed in 10%
formalin and stored at 4 C in PBS. Samples were permeabilized
with 0.025% of Triton X-100/PBS and washed twice with PBS. A
3% BSA/PBS solution was used to block unspecic binding of
the antibodies, with an incubation of 45 min. Aerwards,
samples were incubated in the diluted primary antibody solu-
tion (osteopontin (1 : 50) or osteocalcin (1 : 25)) in 1% BSA/PBS
solution overnight at 4 C. Samples were rinsed in per-
meabilization buﬀer and washed for 10 min in PBS, followed by
incubation with the respective secondary uorochrome-conju-
gated antibody for 2 h at room temperature in the dark. Finally,
samples were incubated with DAPI solution (1/1000), for 15 min
for nuclei staining, followed by incubation with phalloidin
(1/100) for cytoskeletal labeling. Samples were washed with PBS
before observation. An Olympus FluoView™ FV1000 confocal
laser scanning microscope (CLSM) was used to acquire the
images.
Statistical analysis. The normality of the data distribution
was evaluated using the Shapiro–Wilk test (p < 0.05). Since the
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B















































data did not follow a normal distribution, an initial Kruskal–
Wallis test was executed, followed by Dunn's post-test, with a
signicance level of 95% (for cell proliferation, viability and ALP
activity). For the comparisons between groups, t-tests were
performed (qPCR). In all cases, * indicates a signicant diﬀer-
ence with p < 0.05, ** with p < 0.01 and *** with p < 0.001.
3. Results and discussion
3.1 Particles characterization
SiO2 nanoparticles were synthesized using a Sto¨ber-like
approach29 in order to obtain a monodisperse particle size
distribution.30 The SiO2 particle size distribution was deter-
mined by DLS (Table 1), conrming their monodispersive
character, with an average diameter of 240 nm. The SEM
microscopy (Fig. 1) is in agreement with this data, revealing that
the nanoparticles present a spherical morphology, with an
average diameter of 250 nm.
The functionalization of the surface of the SiO2 nano-
particles with PLL and HA was executed using the LbL meth-
odology.31–33 PLL was used to coat the negatively charged Si–OH
surface, followed by HA. The assembling of this bilayered
system was followed by the z-potential of the SiO2 nanoparticles
before and aer the coating with PLL and PLL–HA (Table 1).
The synthesized SiO2 nanoparticles presented a z-potential
of 25 mV at a pH  6, that, upon coating with PLL, changed to
+51 mV due to the positive charge of its amine pending groups.
The surface charge is again switched to negative (z-potential of
35mV) with the coating of HA onto the PLL-coated SiO2. These
data are complemented with the SEM characterization, which
conrms the maintenance of a spherical shape aer the PLL–
HA coating. The SEM image of the SiO2–PLL–HA nanoparticles
also revealed that their average diameter is 400 nm, while the
DLS data indicate an average diameter of 567 nm. This
mismatch can be explained by the hydration of the polymeric
surface bilayer. While the SEM analysis is executed on dry
samples and under vacuum, the DLS data are acquired while the
nanoparticles are maintained on an aqueous suspension, which
enables the hydration of the polymeric coating. In fact, HA is
known for its high hydration capacity that increases its
dimensions in solution.34
The FTIR spectra of PLL, HA, SiO2 and SiO2–PLL–HA are
presented in Fig. 2, while the PLL and HA typical IR peaks (with
their corresponding assignments) are listed in Table 2.9,35,36 The
n(NH) at 3285 cm1 is clearly visible in the PLL spectrum, and its
contribution to the SiO2–PLL–HA spectrum is observed as a
large shoulder to lower wavenumbers of the peak at 3400 cm1
(n(OH) from HA and SiO2). The peaks from the nas(COO
) of HA
at 1655 cm1 and from the n(C]O) of PLL at 1658 cm1 are
observed in the spectrum of SiO2–PLL–HA at 1660 cm
1.36 The
HA spectrum also reveals its ns(COO
) at 1411 cm1, whose
contribution to the SiO2–PLL–HA spectrum is in the form of a
small shoulder at higher wavenumbers, 1520 cm1. The asym-
metric vibration of the n(SiO) with a strong absorption peak at
1090 cm1 also reveals an enlargement due to the inuence of
HA characteristic peaks.37 Finally, the presence of HA in the
SiO2–PLL–HA is further conrmed by the observation in its
spectrum of the d(COO) of HA at 900 cm1.
The collected data conrm the synthesis of monodisperse
core–shell nanoparticles (SiO2–PLL–HA) with SiO2 acting as a
core and the LbL assembled bilayer of PLL–HA as a shell.
3.2 Improvement of the hBMSCs' osteogenic diﬀerentiation
in the presence of the nanoparticles
Cell morphology, proliferation and viability. The eﬀect of
SiO2 concentration on cell viability and proliferation, and
particularly on the osteogenic diﬀerentiation is widely reported
in the literature. Huang et al.5 showed that mesoporous SiO2
nanoparticles, at concentrations ranging from 4 to 200 mgmL1,
do not aﬀect the viability and proliferation of hMSCs. This study
concluded that hMSCs exposed to 40 mg mL1 of nanoparticles
for three days expressed a signicant but transient osteogenic
signal of ALP. On the other hand, Kim et al.38 reported that
mRNA expression levels of OCN and OP, evaluated on human
adipose-derived stem cells cultured in standard osteogenic
diﬀerentiation medium, were higher in the medium containing
98.7 mg mL1 of silicate ions, when compared to 470 mg mL1 of
silicate ions in the culture medium. Finally, Shen et al.39
Table 1 Size and z-potential of the SiO2, SiO2–PLL and SiO2–PLL–HA
nanoparticles
Materials Diametera (nm) PDI z-Potential (mV)
SiO2 240.2  10.9 0.124  0.01 25.0  0.7
SiO2–PLL 270.3  6.7 0.150  0.01 50.6  4.1
SiO2–PLL–HA 567.6  6.5 0.120  0.03 34.9  5.2
a Determined by DLS.
Fig. 1 SEM micrographs of the synthesized SiO2 and SiO2–HA–PLL
nanoparticles.
Fig. 2 FTIR spectra of the PLL, HA, SiO2 and SiO2–PLL–HA after
crosslinking with EDC–NHS.
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demonstrated that 50 mg mL1 of SiO2-based nanoparticles
cultured with MSCs successfully diﬀerentiated into osteocytes,
as demonstrated by ALP activity. Furthermore, this SiO2
concentration did not signicantly aﬀect cell viability and
proliferation. Based on these results, 50 mg mL1 was set as the
maximum concentration of nanoparticles in the culture
medium for the present study.
The synthesized nanoparticles were seeded directly onto
cultured hBMSCs, for diﬀerent time periods (7, 14 and 21 days)
and investigated in terms of their genotypic and phenotypic
features. The morphology of hBMSCs in contact with SiO2 and
SiO2–PLL–HA (50, 25 and 12.5 mg mL
1, named SiO2–PLL–HA,
SiO2–PLL–HA(1/2) and SiO2–PLL–HA(1/4), respectively) was
analysed by SEM (Fig. 3). The hBMSCs exhibited the typical
spindle-shape morphology and cell-to-cell interactions were
also observed as previously reported.40
The eﬀect of SiO2–PLL–HA nanoparticles, at diﬀerent
concentrations, on hBMSC proliferation was also assessed by
measuring the total cells' DNA (Fig. 4). Previous studies of
hBMSC response to SiO2 nanoparticles revealed no evidence of
cytotoxicity for 1–3 days of incubation.5,39,41 From our data, the
same behaviour is observed at days 7, 14 and 21 for the silica
and bilayered silica nanoparticles at all studied concentrations.
Furthermore, hBMSC proliferation results do not show statis-
tically signicant diﬀerences between the cells cultured with
and without nanoparticles at the same time points.
A metabolic activity-based assay (MTS) was also performed at
the diﬀerent time points, in order to determine the hBMSC
viability when cultured in osteogenic culture medium. MTS
results are directly proportional to the number of living cells.42
Our results (Fig. 4) indicate that, at day 7, SiO2 nanoparticles at
a concentration of 50 mg mL1 show a higher viability when
compared to the osteogenic control, indicating that those
nanoparticles are not cytotoxic. At the same time point, the
hBMSCs cultured with SiO2–PLL–HA(1/2) and SiO2–PLL–
HA(1/4) nanoparticles present a highly signicant increase on
viability, when compared to the control. These conditions have
a diﬀerent behavior than the SiO2–PLL–HA. In the latter case,
the cells present a viability comparable to the control. There-
fore, a lower concentration of bilayered silica nanoparticles
induces a higher hBMSC metabolic activity. At day 21, no
signicant diﬀerences were observed, except for SiO2–PLL–HA
which presents a signicantly lower (p < 0.05) metabolic activity
than the cells cultured with SiO2–PLL–HA(1/2).
Genotypic characterization of diﬀerentiated hBMSCs.
Complementary to the reported biological data, the diﬀerenti-
ation level of hBMSCs cultured with SiO2 and SiO2–PLL–HA
nanoparticles was assessed by quantitative PCR of some bone-
specic gene transcripts, namely, ALP, OP, OCN, bone sialo-
protein (BSP), osterix (OSX), Runx-related transcription factor 2
(Runx-2) and collagen type I (Cola). The relative expression of
those genes was normalized against the housekeeping gene
GAPDH and the standard osteogenic culture condition was used
as the calibrator. It is well described that the osteogenic
diﬀerentiation can be subdivided into several developmental
stages: proliferation of stem cells, ECM synthesis, maturation
and ECM mineralization, each with characteristic changes in
the gene expressions rates.43
In this study, each selected gene is responsible for diﬀerent
stages of diﬀerentiation. The transcription factor Runx-2 is a
crucial early marker of the MSCs commitment at the osteogenic
lineage. Runx-2 up-regulates BSP and OCN, two major compo-
nents of the bone ECM synthesized exclusively by osteoblastic
cells.44 While BSP is an osteoblast-enriched gene,45 OCN is the
major non-collagenous protein component of bone ECM and
secreted exclusively by osteoblastic cells at the late stage of
Table 2 Typical vibrational modes of the PLL and HA chemical groups
and their wavenumber assignments
Chemical bond Wavenumber (cm1)
n(OH) hydroxyl groups of HA 3400
n(NH) amine groups of PLL 3285
n(NH) amine groups of PLL 1658
nas(COO
) carboxylate anion of HA 1655
ns(COO
) carboxylate anion of HA 1411
n(COO) carboxylate anion of HA 900
Fig. 3 SEMmicrographs of the morphology of hBMSCs cultured for 7,
14 and 21 days with SiO2 and SiO2–PLL–HA nanoparticles.
Fig. 4 hBMSC proliferation (DNA quantiﬁcation) and viability (MTS
quantiﬁcation) at 7, 14, and 21 days after seeding. Signiﬁcant diﬀer-
ences were represented by * for p < 0.05, ** for p < 0.01 and *** for p <
0.001, as determined by the statistical analysis.
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B















































maturation, and therefore is considered as an indicator of
osteoblast diﬀerentiation.46
From the PCR data (Fig. 5) it is clear that there is an up-
regulation of Runx-2 in the cells cultured with SiO2–PLL–
HA(1/4) at 14 days and SiO2–PLL–HA(1/2) at 7 days. In fact, the
OCN and BSP (usually linked to the Runx-2 expression) are also
overexpressed at the same time point and bilayered nano-
particles' concentration. Unexpectedly, at higher nanoparticle
concentrations, SiO2–PLL–HA, we did not observe the same
trend in the Runx-2 expression. These observations might be
related to the overexpression of Runx-2 in between the time
points chosen for this study, which would limit its detection by
PCR. In the SiO2 case, Runx-2 is overexpressed at 7 days of
culture, although the up-regulation of OCN and BSP is not
observed for SiO2 at any time point. Our data indicate that the
SiO2–PLL–HA(1/2) and SiO2–PLL–HA(1/4) present the most
consistent enhancement of the hBMSC osteogenic diﬀerentia-
tion, through the early osteogenic marker Runx-2, which also
promotes the overexpression of the BSP and OCN genes.
OSX is one of the few characterized osteoblast specic
genes.47 It is known to be a specic osteogenic transcription
factor, which is identied as a late bone marker required for the
diﬀerentiation of preosteoblasts into fully functioning osteo-
blasts.48 The OSX gene expression results showed that, at day 14,
SiO2–PLL–HA(1/4) presents the highest OSX overexpression,
which indicates higher osteogenic activity. These results are
consistent with the observed overexpression of the OCN and
BSP under the same culture conditions (i.e. 14 days and SiO2–
PLL–HA(1/4)).
OP performs important bone related functions, although, it
cannot be considered bone specic since it also plays roles in
kidneys, epithelial lining tissues, blood plasma, and breast
milk.47 Despite this, its gene expression evaluation was not
discarded. OP appears up-regulated mostly at days 7 and 14 for
the SiO2–PLL–HA(1/2) condition. The Cola, as OP, cannot be
considered bone specic, having been identied in numerous
unrelated cell types. However, it is expressed at high levels near
to the end of the proliferative period, which occurs until day 7 of
culture, and during the period of ECM deposition and matu-
ration.49 In fact, Cola gene expression is up-regulated mainly at
day 14 in the presence of SiO2–PLL–HA(1/4) and at day 7 for the
SiO2–PLL–HA(1/2). This observation is in accordance with its
typical early stage expression.
Finally, another bone non-specic gene is the ALP, which is
also expressed at the early stages of the osteogenic diﬀerentia-
tion. At day 7 and 14 we registered an increase of ALP expression
in the cells cultured in the presence of SiO2–PLL–HA(1/2) and
SiO2–PLL–HA(1/4), respectively. These observations are consis-
tent with the overexpression of the other monitored genes for
the same samples, which also showed an up-regulation of genes
Runx-2, OSX, OCN, BSP and Cola, at the same time points.
Summarizing, the gene expression shows relevant diﬀerences in
coated silica nanoparticles with PLL–HA, at lower concentra-
tions, than the SiO2 nanoparticles. In fact, Manferdini et al.50
described that the biomimetic treatment of an HA-based scaf-
fold promotes a faster mineralization process, suggesting its
possible use in clinics as a support for improving bone repair.
ALP activity quantication. ALP, an early stage marker of
osteogenic diﬀerentiation, is an enzyme belonging to a group of
membrane-bound glycoproteins, involved in the pathway result-
ing in the deposition of minerals on ECM molecules.51 The ALP
activity of hBMSCs was assessed as an indicator of the osteogenic
diﬀerentiation. Fig. 6 presents the ALP protein activity expression
proles (mmol ALP per mg protein) of cultured hBMSCs. The
results show that ALP activity values increase progressively with
time under all the diﬀerent experimental conditions, except for
the SiO2–PLL–HA that presents a peak at day 14 and a decrease in
the following time point (this is also in accordance with the gene
expression analysis, where the ALP gene expression is down-
regulated mainly at the latter time points).
In general, the cells' ALP genetic expression is usually
observed before the ALP is actually synthesized by the cells. In
this context, and analyzing these data in combination with the
ALP genetic expression proles, an increase on the activity of
the protein at higher time points would be expected, as
observed for the cells cultured in the presence of lower
concentration of bilayered nanoparticles, i.e. SiO2–PLL–HA(1/2)
and SiO2–PLL–HA(1/4).
Fig. 5 Relative expression of bone-speciﬁc transcripts, namely ALP,
OP, BSP, OCN, Runx-2, OSX and Cola by hBMSCs induced the
diﬀerentiation into the osteogenic lineage over 21 days. The results are
expressed as the means  SD, (*) indicating a signiﬁcant diﬀerence
with p < 0.05, (**) p < 0.01, and (***) p < 0.001. The dashed line
indicates the normalized gene expression of the standard osteogenic
culture conditions.
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Phenotypic characterization of diﬀerentiated hBMSCs. The
immunouorescence staining of matrix-associated proteins
(OCN and OP) were used as markers of hBMSCs osteoblastic
diﬀerentiation. OCN, a bone-specic glycoprotein that binds
calcium and may promote calcication of the bone ECM, has
been used as a late marker of the osteogenic diﬀerentiation.52
OP, synthesized by bone forming cells, is also a phosphoprotein
that possesses several calcium-binding domains and is associ-
ated with cell attachment, proliferation, and mineralization of
the bone ECM.52 Fig. 7 shows the uorescence of the OP and
OCN markers.
In the case of OP, as expected, a delay in the protein
synthesis and its genetic expression is observed. In fact, in all
the cases, there is an initial higher genetic expression (PCR
data) that is accompanied by the protein synthesis at a latter
stage. As an example we observe an OP genetic overexpression
(compared to the control group) in days 7 and 14 for the SiO2–
PLL–HA(1/2) that is followed by a higher OP uorescence in the
cell culture at day 21.
In the case of OCN expression, its deposition in the ECM
under all cultured conditions is clearly visible. Again the genetic
up-regulation occurs at earlier time points (day 7 or 14) for the
SiO2–PLL–HA, SiO2–PLL–HA(1/2) and SiO2–PLL–HA(1/4) nano-
particles, although, the increase in the OP uorescence is only
observed at day 21 (compared to the control sample). This is
again in accordance with the diﬀerent timeframes of genetic
expression and protein deposition, as previously explained.
4. Conclusions
Herein was demonstrated that the proposed SiO2 bilayered
system is able to improve the in vitro osteogenic diﬀerentiation
of hBMSCs, which is dependent on the nanoparticle concen-
tration, without detrimental eﬀect over cell viability and
proliferation. An early in time overexpression of ALP, OCN, OP,
BSP, OSX, Runx-2 and Cola was observed when bilayered
nanoparticles were used in the culture medium. The highest
overexpression of these osteogenesis-related genes was
observed at lower concentrations of nanoparticles (25 mg mL1
and 12.5 mg mL1), being an indication of their osteoinduction
activity. The study shows that bi-layered silica nanoparticles at
low concentrations are potential candidates for applications in
regenerative medicine. These systems can be used as injectable
or a useful component of scaﬀolds for bone tissue regeneration
approaches.
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